This recognition highlights EdiLabs as one of the most exciting VC opportunities in health right now. While the other five finalists were all AI-driven startups, EdiLabs stood out as the sole life sciences company, representing a very different but equally high-potential pathway for venture-scale returns.

Over the next 12 months, EdiLabs will take part in the DEFINE programme, which is designed to support life science and healthtech companies at their earliest stages to navigate the regulatory, clinical, technical, and business risks.

Kuopio is home to more than 1,100 companies in the health sector, alongside Kuopio University Hospital (KUH) and the University of Eastern Finland. Together, they form one of Europe’s most dynamic healthcare ecosystems.

We are delighted to welcome Prof. Emeritus Bruno Conti, PhD to EdiLabs as Scientific Advisor for Pharmacology, Ageing, and Age-Associated Diseases.

Mariliis is a policy strategist with deep expertise at the intersection of science, diplomacy, and innovation.

EdiLabs has been selected to join the PurposeTech Startup Funding Bootcamp, a highly competitive programme designed to help founders become investment-ready.